normative
FDA Evidential Standards Are Too Lenient
The FDA's evidential standard—two positive Phase 3 RCTs in which a drug is any amount better than placebo or a competitor—is far too low, because it specifies neither how much better the drug must be nor what kind of statistical inference is required, making it too easy to approve drugs with a negative benefit-harm profile.
normativepending
Speaker
Jacob StegengaEvidence Quote
“the drug has to be better than placebo; or better than a competitor drug. And, how much better? That's not part of the standard. According to what kind of statistical inference? That's not part of the standard... And that is far, far too low of a standard.”
Created: 6/13/2026, 12:09:58 AM
Your notes
Loading notes...